Những Quan Điểm Hiện Tại Về Hội Chứng Stevens-Johnson và Hoại Tử Biểu Bì Độc

Stevens A, Johnson F (1922) A new eruptive fever associated with stomatitis and ophtalmia; report on two cases in children. Am J Dis Child 24:526–533 Lyell A (1956) Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol 68(11):355–361 Fiessinger R, Rendu R (1917) Sur un syndrome charactérisé par l'inflammation simultanée de toutes les muqueuses externes coexistant avec une éruption vésiculeuse des quatre membres, non douloureuse et non recidivante. Paris Méd 25:54–58 Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC (1993) Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 129(1):92–96 Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schroder W, Roujeau JC (2002) Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 138(8):1019–1024 Pichler WJ (2003) Delayed drug hypersensitivity reactions. Ann Intern Med 139(8):683–693 Chan HL, Stern RS, Arndt KA, Langlois J, Jick SS, Jick H, Walker AM (1990) The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol 126(1):43–47 Hsu DY, Brieva J, Silverberg NB, Silverberg JI (2016) Morbidity and mortality of Stevens-Johnson Syndrome and toxic epidermal necrolysis in United States adults. J Invest Dermatol 136(7):1387–1397. https://doi.org/10.1016/j.jid.2016.03.023 Hsu DY, Brieva J, Silverberg NB, Paller AS, Silverberg JI (2017) Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States. J Am Acad Dermatol 76(5):811–817.e814. https://doi.org/10.1016/j.jaad.2016.12.024 Sakamoto AP, Silva CA, Saad-Magalhaes C, Alencar AN, Pereira RM, Kozu K, Barbosa CM, Terreri MT (2017) Stevens-Johnson syndrome and toxic epidermal necrolysis in childhood-onset systemic lupus erythematosus patients: a multicenter study. Acta Reumatol Port 42(3):250–255 Quirke KP, Beck A, Gamelli RL, Mosier MJ (2015) A 15-year review of pediatric toxic epidermal necrolysis. J Burn Care Res 36(1):130–136. https://doi.org/10.1097/bcr.0000000000000208 Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P (2000) SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 115(2):149–153. https://doi.org/10.1046/j.1523-1747.2000.00061.x Rzany B, Mockenhaupt M, Baur S, Schroder W, Stocker U, Mueller J, Hollander N, Bruppacher R, Schopf E (1996) Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990–1992): structure and results of a population-based registry. J Clin Epidemiol 49(7):769–773 Diphoorn J, Cazzaniga S, Gamba C, Schroeder J, Citterio A, Rivolta AL, Vighi GD, Naldi L (2016) Incidence, causative factors and mortality rates of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in northern Italy: data from the REACT registry. Pharmacoepidemiol Drug Saf 25(2):196–203. https://doi.org/10.1002/pds.3937 Yang MS, Lee JY, Kim J, Kim GW, Kim BK, Kim JY, Park HW, Cho SH, Min KU, Kang HR (2016) Incidence of Stevens-Johnson Syndrome and toxic epidermal necrolysis: a nationwide population-based study using National Health Insurance Database in Korea. PLoS One 11(11):e0165933. https://doi.org/10.1371/journal.pone.0165933 Bloom R, Amber KT (2017) Identifying the incidence of rash, Stevens-Johnson syndrome and toxic epidermal necrolysis in patients taking lamotrigine: a systematic review of 122 randomized controlled trials. An Bras Dermatol 92(1):139–141. https://doi.org/10.1590/abd1806-4841.20175070 Frey N, Jossi J, Bodmer M, Bircher A, Jick SS, Meier CR, Spoendlin J (2017) The Epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in the UK. J Invest Dermatol 137(6):1240–1247. https://doi.org/10.1016/j.jid.2017.01.031 Mittmann N, Knowles SR, Koo M, Shear NH, Rachlis A, Rourke SB (2012) Incidence of toxic epidermal necrolysis and Stevens-Johnson Syndrome in an HIV cohort: an observational, retrospective case series study. Am J Clin Dermatol 13(1):49–54. https://doi.org/10.2165/11593240-000000000-00000 Tseng J, Maurer T, Mutizwa MM (2015) HIV-associated toxic epidermal necrolysis at San Francisco General Hospital: a 13-year retrospective review. J Int Assoc Provid AIDS Care. https://doi.org/10.1177/2325957415614651 Kannenberg SM, Jordaan HF, Koegelenberg CF, Von Groote-Bidlingmaier F, Visser WI (2012) Toxic epidermal necrolysis and Stevens-Johnson syndrome in South Africa: a 3-year prospective study. QJM 105(9):839–846. https://doi.org/10.1093/qjmed/hcs078 Irungu K, Nyamu D, Opanga S (2017) Characterization of Stevens-Johnson syndrome and toxic epidermal necrolysis among patients admitted to kenyatta national hospital: a retrospective cross-sectional study. Drugs Real World Outcomes 4(2):79–85. https://doi.org/10.1007/s40801-017-0105-x Knight L, Todd G, Muloiwa R, Matjila M, Lehloenya RJ (2015) Stevens Johnson syndrome and toxic epidermal necrolysis: maternal and foetal outcomes in twenty-two consecutive pregnant HIV infected women. PLoS One 10(8):e0135501. https://doi.org/10.1371/journal.pone.0135501 Cote B, Wechsler J, Bastuji-Garin S, Assier H, Revuz J, Roujeau JC (1995) Clinicopathologic correlation in erythema multiforme and Stevens-Johnson syndrome. Arch Dermatol 131(11):1268–1272 Roujeau JC (1997) Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme. J Dermatol 24(11):726–729 Rzany B, Hering O, Mockenhaupt M, Schroder W, Goerttler E, Ring J, Schopf E (1996) Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 135(1):6–11 Wetter DA, Davis MD (2010) Recurrent erythema multiforme: clinical characteristics, etiologic associations, and treatment in a series of 48 patients at Mayo Clinic, 2000 to 2007. J Am Acad Dermatol 62(1):45–53. https://doi.org/10.1016/j.jaad.2009.06.046 Schalock PC, Dinulos JG, Pace N, Schwarzenberger K, Wenger JK (2006) Erythema multiforme due to Mycoplasma pneumoniae infection in two children. Pediatr Dermatol 23(6):546–555. https://doi.org/10.1111/j.1525-1470.2006.00307.x Gossart R, Malthiery E, Aguilar F, Torres JH, Fauroux MA (2017) Fuchs syndrome: medical treatment of 1 case and literature review. Case Rep Dermatol 9(1):114–120. https://doi.org/10.1159/000468978 Urosevic-Maiwald M, Kerl K, Harr T, Bogdan Allemann I (2013) Dapsone-induced erythema multiforme with neutropenia in a patient with linear IgA dermatosis: case report and review of the literature. Int J Dermatol 52(11):1369–1371. https://doi.org/10.1111/j.1365-4632.2011.05413.x Prieto-Barrios M, Velasco-Tamariz V, Tous-Romero F, Burillo-Martinez S, Zarco-Olivo C, Rodriguez-Peralto JL, Ortiz-Romero PL (2017) Linear immunoglobulin A dermatosis mimicking toxic epidermal necrolysis: a case report of etanercept treatment. Br J Dermatol. https://doi.org/10.1111/bjd.15400 Pereira AR, Moura LH, Pinheiro JR, Pasin VP, Enokihara MM, Porro AM (2016) Vancomycin-associated linear IgA disease mimicking toxic epidermal necrolysis. An Bras Dermatol 91(5 suppl 1):35–38. https://doi.org/10.1590/abd1806-4841.20164665 Chanal J, Ingen-Housz-Oro S, Ortonne N, Duong TA, Thomas M, Valeyrie-Allanore L, Lebrun-Vignes B, Andre C, Roujeau JC, Chosidow O, Wolkenstein P (2013) Linear IgA bullous dermatosis: comparison between the drug-induced and spontaneous forms. Br J Dermatol 169(5):1041–1048. https://doi.org/10.1111/bjd.12488 Kakar R, Paugh H, Jaworsky C (2013) Linear IgA bullous disease presenting as toxic epidermal necrolysis: a case report and review of the literature. Dermatology 227(3):209–213. https://doi.org/10.1159/000353584 Adler NR, McLean CA, Aung AK, Goh MS (2017) Piperacillin-tazobactam-induced linear IgA bullous dermatosis presenting clinically as Stevens-Johnson syndrome/toxic epidermal necrolysis overlap. Clin Exp Dermatol 42(3):299–302. https://doi.org/10.1111/ced.13030 Schroeder D, Saada D, Rafaa M, Ingen-Housz-Oro S, Valeyrie-Allanore L, Sigal ML (2011) Verapamil-induced linear IgA disease mimicking toxic epidermal necrolysis. Ann Dermatol Venereol 138(4):302–306. https://doi.org/10.1016/j.annder.2010.10.028 Madan V, Jamieson LA, Bhogal BS, Wong CS (2009) Inflammatory epidermolysis bullosa acquisita mimicking toxic epidermal necrolysis and dermatitis herpetiformis. Clin Exp Dermatol 34(8):e705–e708. https://doi.org/10.1111/j.1365-2230.2009.03439.x Yamada T, Nakamura S, Demitsu T, Nakamura T, Iida E, Yoneda K, Fukuda S, Hashimoto T (2013) Paraneoplastic pemphigus mimicking toxic epidermal necrolysis associated with B-cell lymphoma. J Dermatol 40(4):286–288. https://doi.org/10.1111/1346-8138.12083 Wakumoto-Nakashima K, Yoshida Y, Adachi K, Yamamoto O, Hashimoto T (2013) Rare appearance of toxic epidermal necrolysis-like histopathological features in a case of atypical pemphigus with serological pemphigus vulgaris character. J Dermatol 40(1):63–64. https://doi.org/10.1111/j.1346-8138.2012.01667.x Sebaratnam DF, Murrell DF (2011) Bullous systemic lupus erythematosus. Dermatol Clin 29(4):649–653. https://doi.org/10.1016/j.det.2011.06.002 Vassileva S (2004) Bullous systemic lupus erythematosus. Clin Dermatol 22(2):129–138. https://doi.org/10.1016/j.clindermatol.2003.12.020 Lee HY, Tey HL, Pang SM, Thirumoorthy T (2011) Systemic lupus erythematosus presenting as Stevens-Johnson syndrome and toxic epidermal necrolysis: a report of three cases. Lupus 20(6):647–652. https://doi.org/10.1177/0961203310385162 Mandelcorn R, Shear NH (2003) Lupus-associated toxic epidermal necrolysis: a novel manifestation of lupus? J Am Acad Dermatol 48(4):525–529. https://doi.org/10.1067/mjd.2003.107 Yu J, Brandling-Bennett H, Co DO, Nocton JJ, Stevens AM, Chiu YE (2016) Toxic epidermal necrolysis-like cutaneous lupus in pediatric patients: a case series and review. Pediatrics 137(6). https://doi.org/10.1542/peds.2015-4497 Correia O, Delgado L, Barbosa IL, Domingues JC, Azevedo R, Vaz CP, Pimentel P (2001) CD8+ lymphocytes in the blister fluid of severe acute cutaneous graft-versus-host disease: further similarities with toxic epidermal necrolysis. Dermatology 203(3):212–216 Naik H, Lockwood S, Saavedra A (2017) A pilot study comparing histological and immunophenotypic patterns in stage 4 skin graft vs host disease from toxic epidermal necrolysis. J Cutan Pathol. https://doi.org/10.1111/cup.12986 Villada G, Roujeau JC, Cordonnier C, Bagot M, Kuentz M, Wechsler J, Vernant JP (1990) Toxic epidermal necrolysis after bone marrow transplantation: study of nine cases. J Am Acad Dermatol 23(5 Pt 1):870–875 Melish ME, Glasgow LA (1970) The staphylococcal scalded-skin syndrome. N Engl J Med 282(20):1114–1119. https://doi.org/10.1056/nejm197005142822002 Melish ME, Glasgow LA, Turner MD (1972) The staphylococcal scalded-skin syndrome: isolation and partial characterization of the exfoliative toxin. J Infect Dis 125(2):129–140 Su J, Li J, Luo H, Xiao Z, Luo B, Chen X, Li J, Liu P, Zhu W (2016) Demographic and clinical characteristics and risk factors for Staphylococcal scalded skin syndrome in Hunan. J Cent S Univ Med Sci 41(4):417–421. 10.11817/j.issn.1672-7347.2016.04.013 Handler MZ, Schwartz RA (2014) Staphylococcal scalded skin syndrome: diagnosis and management in children and adults. J Eur Acad Dermatol Venereol 28(11):1418–1423. https://doi.org/10.1111/jdv.12541 Miyashita K, Ogawa K, Iioka H, Miyagawa F, Okazaki A, Kobayashi N, Asada H (2016) Adult case of staphylococcal scalded skin syndrome differentiated from toxic epidermal necrolysis with the aid of dermoscopy. J Dermatol 43(7):842–843. https://doi.org/10.1111/1346-8138.13281 Cho YT, Lin JW, Chen YC, Chang CY, Hsiao CH, Chung WH, Chu CY (2014) Generalized bullous fixed drug eruption is distinct from Stevens-Johnson syndrome/toxic epidermal necrolysis by immunohistopathological features. J Am Acad Dermatol 70(3):539–548. https://doi.org/10.1016/j.jaad.2013.11.015 Alniemi DT, Wetter DA, Bridges AG, El-Azhary RA, Davis MD, Camilleri MJ, McEvoy MT (2017) Acute generalized exanthematous pustulosis: clinical characteristics, etiologic associations, treatments, and outcomes in a series of 28 patients at Mayo Clinic, 1996–2013. Int J Dermatol 56(4):405–414. https://doi.org/10.1111/ijd.13434 Pierard-Franchimont C, Lesuisse M, Humbert P, Delvenne P, Pierard GE (2012) Toxic epidermal necrolysis and antifolate drugs in cancer chemotherapy. Curr Drug Saf 7(5):357–360 Chen TJ, Chung WH, Chen CB, Hui RC, Huang YH, Lu YT, Wang CW, Wang KH, Yang LC, Hung SI (2017) Methotrexate-induced epidermal necrosis: a case series of 24 patients. J Am Acad Dermatol 77(2):247–255.e242. https://doi.org/10.1016/j.jaad.2017.02.021 Quinn AM, Brown K, Bonish BK, Curry J, Gordon KB, Sinacore J, Gamelli R, Nickoloff BJ (2005) Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysis. Arch Dermatol 141(6):683–687. https://doi.org/10.1001/archderm.141.6.683 Valeyrie-Allanore L, Bastuji-Garin S, Guegan S, Ortonne N, Bagot M, Roujeau JC, Revuz JE, Wechsler J, Wolkenstein P (2013) Prognostic value of histologic features of toxic epidermal necrolysis. J Am Acad Dermatol 68(2):e29–e35. https://doi.org/10.1016/j.jaad.2011.10.007 Samhaber KT, Bertsch HP, Schon MP, Haenssle HA (2017) In vivo reflectance confocal microscopy of erythema multiforme and Stevens-Johnson syndrome: a histopathological correlation based on a case series. J Ger Soc Dermatol 15(5):573–576. https://doi.org/10.1111/ddg.12975 Roujeau JC, Stern RS (1994) Severe adverse cutaneous reactions to drugs. N Engl J Med 331(19):1272–1285. https://doi.org/10.1056/nejm199411103311906 Palmieri TL, Greenhalgh DG, Saffle JR, Spence RJ, Peck MD, Jeng JC, Mozingo DW, Yowler CJ, Sheridan RL, Ahrenholz DH, Caruso DM, Foster KN, Kagan RJ, Voigt DW, Purdue GF, Hunt JL, Wolf S, Molitor F (2002) A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century. J Burn Care Rehabil 23(2):87–96 Cartotto R, Mayich M, Nickerson D, Gomez M (2008) SCORTEN accurately predicts mortality among toxic epidermal necrolysis patients treated in a burn center. J Burn Care Res 29(1):141–146. https://doi.org/10.1097/BCR.0b013e31815f3865 Mahar PD, Wasiak J, Cleland H, Watters D, Paul E, Marsh P, Gin D (2013) Mortality and use of the auxiliary score in extensive toxic epidermal necrolysis patients admitted to an adult burns referral centre. Dermatology 227(2):180–185. https://doi.org/10.1159/000354264 Firoz BF, Henning JS, Zarzabal LA, Pollock BH (2012) Toxic epidermal necrolysis: five years of treatment experience from a burn unit. J Am Acad Dermatol 67(4):630–635. https://doi.org/10.1016/j.jaad.2011.12.014 Chantaphakul H, Sanon T, Klaewsongkram J (2015) Clinical characteristics and treatment outcome of Stevens-Johnson syndrome and toxic epidermal necrolysis. Exp Ther Med 10(2):519–524. https://doi.org/10.3892/etm.2015.2549 Barron SJ, Del Vecchio MT, Aronoff SC (2015) Intravenous immunoglobulin in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a meta-analysis with meta-regression of observational studies. Int J Dermatol 54(1):108–115. https://doi.org/10.1111/ijd.12423 Hu CH, Chang NJ, Liu EK, Chuang SS, Chung WH, Yang JY (2013) SCORTEN and impaired renal function related to mortality of toxic epidermal necrolysis syndrome patients in the Asian population. J Eur Acad Dermatol Venereol 27(5):628–633. https://doi.org/10.1111/j.1468-3083.2012.04502.x Guegan S, Bastuji-Garin S, Poszepczynska-Guigne E, Roujeau JC, Revuz J (2006) Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Invest Dermatol 126(2):272–276. https://doi.org/10.1038/sj.jid.5700068 Bansal S, Garg VK, Sardana K, Sarkar R (2015) A clinicotherapeutic analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis with an emphasis on the predictive value and accuracy of SCORe of toxic epidermal necrolysis. Int J Dermatol 54(1):e18–e26. https://doi.org/10.1111/ijd.12466 Sekula P, Liss Y, Davidovici B, Dunant A, Roujeau JC, Kardaun S, Naldi L, Schumacher M, Mockenhaupt M (2011) Evaluation of SCORTEN on a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis included in the RegiSCAR study. J Burn Care Res 32(2):237–245. https://doi.org/10.1097/BCR.0b013e31820aafbc Sorrell J, Anthony L, Rademaker A, Belknap SM, Callahan S, West DP, Paller AS (2017) Score of toxic epidermal necrosis predicts the outcomes of pediatric epidermal necrolysis. Pediatr Dermatol 34(4):433–437. https://doi.org/10.1111/pde.13172 Wong DT, Knaus WA (1991) Predicting outcome in critical care: the current status of the APACHE prognostic scoring system. Can J Anaesth 38(3):374–383. https://doi.org/10.1007/bf03007629 George SM, Harrison DA, Welch CA, Nolan KM, Friedmann PS (2008) Dermatological conditions in intensive care: a secondary analysis of the Intensive Care National Audit and Research Centre (ICNARC) Case Mix Programme database. Crit Care 12(Suppl 1):S1. https://doi.org/10.1186/cc6141 Sassolas B, Haddad C, Mockenhaupt M, Dunant A, Liss Y, Bork K, Haustein UF, Vieluf D, Roujeau JC, Le Louet H (2010) ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther 88(1):60–68. https://doi.org/10.1038/clpt.2009.252 Chung WH, Hung SI, Yang JY, Su SC, Huang SP, Wei CY, Chin SW, Chiou CC, Chu SC, Ho HC, Yang CH, Lu CF, Wu JY, Liao YD, Chen YT (2008) Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med 14(12):1343–1350. https://doi.org/10.1038/nm.1884 Abe R, Yoshioka N, Murata J, Fujita Y, Shimizu H (2009) Granulysin as a marker for early diagnosis of the Stevens-Johnson syndrome. Ann Intern Med 151(7):514–515 Murata J, Abe R, Shimizu H (2008) Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment. J Allergy Clin Immunol 122(5):992–1000. https://doi.org/10.1016/j.jaci.2008.06.013 Fujita Y, Yoshioka N, Abe R, Murata J, Hoshina D, Mae H, Shimizu H (2011) Rapid immunochromatographic test for serum granulysin is useful for the prediction of Stevens-Johnson syndrome and toxic epidermal necrolysis. J Am Acad Dermatol 65(1):65–68. https://doi.org/10.1016/j.jaad.2010.04.042 Stur K, Karlhofer FM, Stingl G (2007) Soluble FAS ligand: a discriminating feature between drug-induced skin eruptions and viral exanthemas. J Invest Dermatol 127(4):802–807. https://doi.org/10.1038/sj.jid.5700648 Yang Y, Li F, Du J, Shen Y, Lin J, Zhu X, Luo X, Liang J, Xu J (2016) Variable levels of apoptotic signal-associated cytokines in the disease course of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. Australas J Dermatol. https://doi.org/10.1111/ajd.12462 Quaglino P, Caproni M, Antiga E, Del Bianco E, Osella-Abate S, Savoia P, Frezzolini A, Schena D, Marzano A, Volpi W, De Simone C, Parodi A, Fabbri P, Bernengo MG (2007) Serum levels of the Th1 promoter IL-12 and the Th2 chemokine TARC are elevated in erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis and correlate with soluble Fas ligand expression. An immunoenzymatic study from the Italian Group of Immunopathology. Dermatology 214(4):296–304. https://doi.org/10.1159/000100880 Komatsu-Fujii T, Kaneko S, Chinuki Y, Suyama Y, Ohta M, Niihara H, Morita E (2017) Serum TARC levels are strongly correlated with blood eosinophil count in patients with drug eruptions. Allergol Int 66(1):116–122. https://doi.org/10.1016/j.alit.2016.06.003 Su SC, Mockenhaupt M, Wolkenstein P, Dunant A, Le Gouvello S, Chen CB, Chosidow O, Valeyrie-Allanore L, Bellon T, Sekula P, Wang CW, Schumacher M, Kardaun SH, Hung SI, Roujeau JC, Chung WH (2017) Interleukin-15 Is associated with severity and mortality in Stevens-Johnson syndrome/toxic epidermal necrolysis. J Invest Dermatol 137(5):1065–1073. https://doi.org/10.1016/j.jid.2016.11.034 Sato S, Ichihara A, Jinnin M, Izuno Y, Fukushima S, Ihn H (2015) Serum miR-124 up-regulation as a disease marker of toxic epidermal necrolysis. Eur J Dermatol 25(5):457–462. https://doi.org/10.1684/ejd.2015.2621 Wolkenstein P, Chosidow O, Flechet ML, Robbiola O, Paul M, Dume L, Revuz J, Roujeau JC (1996) Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Contact Dermatitis 35(4):234–236 Balachandran C, Shenoi SD, Sarkar D, Ravikumar BC (2002) Patch tests in adverse cutaneous drug reaction. Indian J Dermatol Venereol Leprol 68(1):13–15 Barbaud A, Collet E, Milpied B, Assier H, Staumont D, Avenel-Audran M, Grange A, Amarger S, Girardin P, Guinnepain MT, Truchetet F, Lasek A, Waton J (2013) A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions. Br J Dermatol 168(3):555–562. https://doi.org/10.1111/bjd.12125 Shiny TN, Mahajan VK, Mehta KS, Chauhan PS, Rawat R, Sharma R (2017) Patch testing and cross sensitivity study of adverse cutaneous drug reactions due to anticonvulsants: a preliminary report. World J Methodol 7(1):25–32. https://doi.org/10.5662/wjm.v7.i1.25 Lin YT, Chang YC, Hui RC, Yang CH, Ho HC, Hung SI, Chung WH (2013) A patch testing and cross-sensitivity study of carbamazepine-induced severe cutaneous adverse drug reactions. J Eur Acad Dermatol Venereol 27(3):356–364. https://doi.org/10.1111/j.1468-3083.2011.04418.x Lehloenya RJ, Todd G, Wallace J, Ngwanya MR, Muloiwa R, Dheda K (2016) Diagnostic patch testing following tuberculosis-associated cutaneous adverse drug reactions induces systemic reactions in HIV-infected persons. Br J Dermatol 175(1):150–156. https://doi.org/10.1111/bjd.14492 Pichler WJ, Tilch J (2004) The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy 59(8):809–820. https://doi.org/10.1111/j.1398-9995.2004.00547.x Karami Z, Mesdaghi M, Karimzadeh P, Mansouri M, Taghdiri MM, Kayhanidoost Z, Jebelli B, Shekarriz Foumani R, Babaie D, Chavoshzadeh Z (2016) Evaluation of lymphocyte transformation test results in patients with delayed hypersensitivity reactions following the use of anticonvulsant drugs. Int Arch Allergy Immunol 170(3):158–162. https://doi.org/10.1159/000448284 Tang YH, Mockenhaupt M, Henry A, Bounoua M, Naldi L, Le Gouvello S, Bensussan A, Roujeau JC (2012) Poor relevance of a lymphocyte proliferation assay in lamotrigine-induced Stevens-Johnson syndrome or toxic epidermal necrolysis. Clin Exp Allergy 42(2):248–254. https://doi.org/10.1111/j.1365-2222.2011.03875.x Kano Y, Hirahara K, Mitsuyama Y, Takahashi R, Shiohara T (2007) Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption. Allergy 62(12):1439–1444. https://doi.org/10.1111/j.1398-9995.2007.01553.x Srinoulprasert Y, Pichler WJ (2014) Enhancement of drug-specific lymphocyte proliferation using CD25(hi)-depleted CD3(+) effector cells. Int Arch Allergy Immunol 163(3):198–205. https://doi.org/10.1159/000358491 Beeler A, Zaccaria L, Kawabata T, Gerber BO, Pichler WJ (2008) CD69 upregulation on T cells as an in vitro marker for delayed-type drug hypersensitivity. Allergy 63(2):181–188. https://doi.org/10.1111/j.1398-9995.2007.01516.x Kato K, Kawase A, Azukizawa H, Hanafusa T, Nakagawa Y, Murota H, Sakaguchi S, Asada H, Katayama I (2017) Novel interferon-gamma enzyme-linked immunoSpot assay using activated cells for identifying hypersensitivity-inducing drug culprits. J Dermatol Sci 86(3):222–229. https://doi.org/10.1016/j.jdermsci.2017.03.007 Klaewsongkram J, Thantiworasit P, Suthumchai N, Rerknimitr P, Sukasem C, Tuchinda P, Chularojanamontri L, Srinoulprasert Y, Rerkpattanapipat T, Chanprapaph K, Disphanurat W, Chakkavittumrong P, Tovanabutra N, Srisuttiyakorn C (2016) In vitro test to confirm diagnosis of allopurinol-induced severe cutaneous adverse reactions. Br J Dermatol 175(5):994–1002. https://doi.org/10.1111/bjd.14701 Porebski G, Pecaric-Petkovic T, Groux-Keller M, Bosak M, Kawabata TT, Pichler WJ (2013) In vitro drug causality assessment in Stevens-Johnson syndrome—alternatives for lymphocyte transformation test. Clin Exp Allergy 43(9):1027–1037. https://doi.org/10.1111/cea.12145 Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, Sidoroff A, Schneck J, Roujeau JC, Flahault A (2008) Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 128(1):35–44. https://doi.org/10.1038/sj.jid.5701033 Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, Auquier A, Bastuji-Garin S, Correia O, Locati F et al (1995) Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 333(24):1600–1607. https://doi.org/10.1056/nejm199512143332404 Halevy S, Ghislain PD, Mockenhaupt M, Fagot JP, Bouwes Bavinck JN, Sidoroff A, Naldi L, Dunant A, Viboud C, Roujeau JC (2008) Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 58(1):25–32. https://doi.org/10.1016/j.jaad.2007.08.036 Miliszewski MA, Kirchhof MG, Sikora S, Papp A, Dutz JP (2016) Stevens-Johnson Syndrome and toxic epidermal necrolysis: an analysis of triggers and implications for improving prevention. Am J Med 129(11):1221–1225. https://doi.org/10.1016/j.amjmed.2016.03.022 Maggio N, Firer M, Zaid H, Bederovsky Y, Aboukaoud M, Gandelman-Marton R, Noyman I, Ekstein D, Blatt I, Marom E, Schwartzberg E, Israel S, Ingber A, Brautbar C, Eyal S (2017) Causative drugs of Stevens-Johnson syndrome and toxic epidermal necrolysis in Israel. J Clin Pharmacol 57(7):823–829. https://doi.org/10.1002/jcph.873 Patel TK, Barvaliya MJ, Sharma D, Tripathi C (2013) A systematic review of the drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Indian population. Indian J Dermatol Venereol Leprol 79(3):389–398. https://doi.org/10.4103/0378-6323.110749 Levi N, Bastuji-Garin S, Mockenhaupt M, Roujeau JC, Flahault A, Kelly JP, Martin E, Kaufman DW, Maison P (2009) Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics 123(2):e297–e304. https://doi.org/10.1542/peds.2008-1923 Bosak M, Porebski G, Slowik A, Turaj W (2017) Common allergies do not influence the prevalence of cutaneous hypersensitivity reactions to antiepileptic drugs. Epilepsy Res 135:9–13. https://doi.org/10.1016/j.eplepsyres.2017.05.006 Kumar Das K, Khondokar S, Rahman A, Chakraborty A (2014) Unidentified drugs in traditional medications causing toxic epidermal necrolysis: a developing country experience. Int J Dermatol 53(4):510–515. https://doi.org/10.1111/ijd.12253 Vivar KL, Deschaine M, Messina J, Divine JM, Rabionet A, Patel N, Harrington MA, Seminario-Vidal L (2017) Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy. J Cutan Pathol 44(4):381–384. https://doi.org/10.1111/cup.12876 Nayar N, Briscoe K, Fernandez Penas P (2016) Toxic epidermal necrolysis-like reaction with severe satellite cell necrosis associated with nivolumab in a patient with ipilimumab refractory metastatic melanoma. J Immunother 39(3):149–152. https://doi.org/10.1097/cji.0000000000000112 Urosevic-Maiwald M, Harr T, French LE, Dummer R (2012) Stevens-Johnson syndrome and toxic epidermal necrolysis overlap in a patient receiving cetuximab and radiotherapy for head and neck cancer. Int J Dermatol 51(7):864–867. https://doi.org/10.1111/j.1365-4632.2011.05356.x Lee SS, Chu PY (2010) Toxic epidermal necrolysis caused by cetuximab plus minocycline in head and neck cancer. Am J Otolaryngol 31(4):288–290. https://doi.org/10.1016/j.amjoto.2009.02.021 Lin WL, Lin WC, Yang JY, Chang YC, Ho HC, Yang LC, Yang CH, Hung SI, Chung WH (2008) Fatal toxic epidermal necrolysis associated with cetuximab in a patient with colon cancer. J Clin Oncol Off J Am Soc Clin Oncol 26(16):2779–2780. https://doi.org/10.1200/jco.2007.15.7883 Bellon T, Lerma V, Gonzalez-Valle O, Gonzalez Herrada C, de Abajo FJ (2016) Vemurafenib-induced toxic epidermal necrolysis: possible cross-reactivity with other sulfonamide compounds. Br J Dermatol 174(3):621–624. https://doi.org/10.1111/bjd.14201 Jeudy G, Dalac-Rat S, Bonniaud B, Hervieu A, Petrella T, Collet E, Vabres P (2015) Successful switch to dabrafenib after vemurafenib-induced toxic epidermal necrolysis. Br J Dermatol 172(5):1454–1455. https://doi.org/10.1111/bjd.13522 Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, Wu JY, Chen YT (2004) Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428(6982):486. https://doi.org/10.1038/428486a Ou GJ, Wang J, Ji X, Yu H, Jiang L, Li L, Chen Q, Su PC, Liu Z (2017) A study of HLA-B*15:02 in 9 different Chinese ethnics: implications for carbamazepine related SJS/TEN. HLA 89(4):225–229. https://doi.org/10.1111/tan.12970 Khor AH, Lim KS, Tan CT, Kwan Z, Tan WC, Wu DB, Ng CC (2017) HLA-A*31: 01 and HLA-B*15:02 association with Stevens-Johnson syndrome and toxic epidermal necrolysis to carbamazepine in a multiethnic Malaysian population. Pharmacogenet Genomics 27(7):275–278. https://doi.org/10.1097/fpc.0000000000000287 Locharernkul C, Loplumlert J, Limotai C, Korkij W, Desudchit T, Tongkobpetch S, Kangwanshiratada O, Hirankarn N, Suphapeetiporn K, Shotelersuk V (2008) Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia 49(12):2087–2091. https://doi.org/10.1111/j.1528-1167.2008.01719.x Mehta TY, Prajapati LM, Mittal B, Joshi CG, Sheth JJ, Patel DB, Dave DM, Goyal RK (2009) Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. Indian J Dermatol Venereol Leprol 75(6):579–582. https://doi.org/10.4103/0378-6323.57718 Park HJ, Kim YJ, Kim DH, Kim J, Park KH, Park JW, Lee JH (2016) HLA allele frequencies in 5802 Koreans: varied allele types associated with SJS/TEN according to culprit drugs. Yonsei Med J 57(1):118–126. https://doi.org/10.3349/ymj.2016.57.1.118 Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, Furuya H, Takahashi Y, Muramatsu M, Kinoshita S, Abe M, Ikeda H, Kashiwagi M, Song Y, Ueta M, Sotozono C, Ikezawa Z, Hasegawa R (2010) HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia 51(12):2461–2465. https://doi.org/10.1111/j.1528-1167.2010.02766.x Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, Sawada J, Furuya H, Takahashi Y, Muramatsu M, Kinoshita S, Abe M, Ikeda H, Kashiwagi M, Song Y, Ueta M, Sotozono C, Ikezawa Z, Hasegawa R (2008) HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 9(11):1617–1622. https://doi.org/10.2217/14622416.9.11.1617 Lonjou C, Borot N, Sekula P, Ledger N, Thomas L, Halevy S, Naldi L, Bouwes-Bavinck JN, Sidoroff A, de Toma C, Schumacher M, Roujeau JC, Hovnanian A, Mockenhaupt M (2008) A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 18(2):99–107. https://doi.org/10.1097/FPC.0b013e3282f3ef9c Alfirevic A, Jorgensen AL, Williamson PR, Chadwick DW, Park BK, Pirmohamed M (2006) HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 7(6):813–818. https://doi.org/10.2217/14622416.7.6.813 Ramirez E, Bellon T, Tong HY, Borobia AM, de Abajo FJ, Lerma V, Moreno Hidalgo MA, Castaner JL, Cabanas R, Fiandor A, Gonzalez-Ramos J, Herranz P, Cachafeiro L, Gonzalez-Herrada C, Gonzalez O, Aramburu JA, Laosa O, Hernandez R, Carcas AJ, Frias J (2017) Significant HLA class I type associations with aromatic antiepileptic drug (AED)-induced SJS/TEN are different from those found for the same AED-induced DRESS in the Spanish population. Pharmacol Res 115:168–178. https://doi.org/10.1016/j.phrs.2016.11.027 Ferrell PB Jr, McLeod HL (2008) Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics 9(10):1543–1546. https://doi.org/10.2217/14622416.9.10.1543 Gunathilake KM, Wettasinghe KT, Dissanayake VH (2016) A study of HLA-B *15:02 in a Sri Lankan population: implications for pharmacogenomic testing. Hum Immunol 77(5):429–431. https://doi.org/10.1016/j.humimm.2016.04.001 Hung SI, Chung WH, Liu ZS, Chen CH, Hsih MS, Hui RC, Chu CY, Chen YT (2010) Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics 11(3):349–356. https://doi.org/10.2217/pgs.09.162 Chen CB, Hsiao YH, Wu T, Hsih MS, Tassaneeyakul W, Jorns TP, Sukasem C, Hsu CN, Su SC, Chang WC, Hui RC, Chu CY, Chen YJ, Wu CY, Hsu CK, Chiu TM, Sun PL, Lee HE, Yang CY, Kao PH, Yang CH, Ho HC, Lin JY, Chang YC, Chen MJ, CW L, Ng CY, Kuo KL, Lin CY, Yang CS, Chen DP, Chang PY, Wu TL, Lin YJ, Weng YC, Kuo TT, Hung SI, Chung WH (2017) Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians. Neurology 88(1):78–86. https://doi.org/10.1212/wnl.0000000000003453 Chang CC, Ng CC, Too CL, Choon SE, Lee CK, Chung WH, Hussein SH, Lim KS, Murad S (2017) Association of HLA-B*15:13 and HLA-B*15:02 with phenytoin-induced severe cutaneous adverse reactions in a Malay population. Pharmacogenomics J 17(2):170–173. https://doi.org/10.1038/tpj.2016.10 Tassaneeyakul W, Prabmeechai N, Sukasem C, Kongpan T, Konyoung P, Chumworathayi P, Tiamkao S, Khunarkornsiri U, Kulkantrakorn K, Saksit N, Nakkam N, Satapornpong P, Vannaprasaht S, Sangviroon A, Mahasirimongkol S, Wichukchinda N, Rerkpattanapipat T, Tassaneeyakul W (2016) Associations between HLA class I and cytochrome P450 2C9 genetic polymorphisms and phenytoin-related severe cutaneous adverse reactions in a Thai population. Pharmacogenet Genomics 26(5):225–234. https://doi.org/10.1097/fpc.0000000000000211 Shi YW, Min FL, Zhou D, Qin B, Wang J, FY H, Cheung YK, Zhou JH, Hu XS, Zhou JQ, Zhou LM, Zheng ZZ, Pan J, He N, Liu ZS, Hou YQ, Lim KS, Ou YM, Hui-Ping Khor A, Ng CC, Mao BJ, Liu XR, Li BM, Kuan YY, Yi YH, He XL, Deng XY, Su T, Kwan P, Liao WP (2017) HLA-A*24:02 as a common risk factor for antiepileptic drug-induced cutaneous adverse reactions. Neurology 88(23):2183–2191. https://doi.org/10.1212/wnl.0000000000004008 Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, Lin YL, Lan JL, Yang LC, Hong HS, Chen MJ, Lai PC, Wu MS, Chu CY, Wang KH, Chen CH, Fann CS, Wu JY, Chen YT (2005) HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 102(11):4134–4139. https://doi.org/10.1073/pnas.0409500102 Tassaneeyakul W, Jantararoungtong T, Chen P, Lin PY, Tiamkao S, Khunarkornsiri U, Chucherd P, Konyoung P, Vannaprasaht S, Choonhakarn C, Pisuttimarn P, Sangviroon A, Tassaneeyakul W (2009) Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics 19(9):704–709. https://doi.org/10.1097/FPC.0b013e328330a3b8 Niihara H, Kaneko S, Ito T, Sugamori T, Takahashi N, Kohno K, Morita E (2013) HLA-B*58:01 strongly associates with allopurinol-induced adverse drug reactions in a Japanese sample population. J Dermatol Sci 71(2):150–152. https://doi.org/10.1016/j.jdermsci.2013.04.013 Ke CH, Chung WH, Wen YH, Huang YB, Chuang HY, Tain YL, Wang YL, Wu CC, Hsu CN (2017) Cost-effectiveness analysis for genotyping before allopurinol treatment to prevent severe cutaneous adverse drug reactions. J Rheumatol 44(6):835–843. https://doi.org/10.3899/jrheum.151476 Jutkowitz E, Dubreuil M, Lu N, Kuntz KM, Choi HK (2017) The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States. Semin Arthritis Rheum 46(5):594–600. https://doi.org/10.1016/j.semarthrit.2016.10.009 Yang F, Xuan J, Chen J, Zhong H, Luo H, Zhou P, Sun X, He L, Chen S, Cao Z, Luo X, Xing Q (2016) HLA-B*59:01: a marker for Stevens-Johnson syndrome/toxic epidermal necrolysis caused by methazolamide in Han Chinese. Pharmacogenomics J 16(1):83–87. https://doi.org/10.1038/tpj.2015.25 Kim SH, Kim M, Lee KW, Kim SH, Kang HR, Park HW, Jee YK (2010) HLA-B*5901 is strongly associated with methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. Pharmacogenomics 11(6):879–884. https://doi.org/10.2217/pgs.10.54 Kongpan T, Mahasirimongkol S, Konyoung P, Kanjanawart S, Chumworathayi P, Wichukchinda N, Kidkeukarun R, Preechakul S, Khunarkornsiri U, Bamrungram W, Supharatwattanakun B, Mootsikapun P, Kwangsukstid S, Denjanta S, Vannaprasaht S, Rungapiromnan W, Suwankesawong W, Tassaneeyakul W, Tassaneeyakul W (2015) Candidate HLA genes for prediction of co-trimoxazole-induced severe cutaneous reactions. Pharmacogenet Genomics 25(8):402–411. https://doi.org/10.1097/fpc.0000000000000153 Ueta M, Sawai H, Shingaki R, Kawai Y, Sotozono C, Kojima K, Yoon KC, Kim MK, Seo KY, Joo CK, Nagasaki M, Kinoshita S, Tokunaga K (2017) Genome-wide association study using the ethnicity-specific Japonica array: identification of new susceptibility loci for cold medicine-related Stevens-Johnson syndrome with severe ocular complications. J Hum Genet 62(4):485–489. https://doi.org/10.1038/jhg.2016.160 Ciccacci C, Latini A, Politi C, Mancinelli S, Marazzi MC, Novelli G, Palombi L, Borgiani P (2017) Impact of glutathione transferases genes polymorphisms in nevirapine adverse reactions: a possible role for GSTM1 in SJS/TEN susceptibility. Eur J Clin Pharmacol. https://doi.org/10.1007/s00228-017-2295-2 Le Cleach L, Delaire S, Boumsell L, Bagot M, Bourgault-Villada I, Bensussan A, Roujeau JC (2000) Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors. Clin Exp Immunol 119(1):225–230 Tohyama M, Watanabe H, Murakami S, Shirakata Y, Sayama K, Iijima M, Hashimoto K (2012) Possible involvement of CD14+ CD16+ monocyte lineage cells in the epidermal damage of Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 166(2):322–330. https://doi.org/10.1111/j.1365-2133.2011.10649.x Correia O, Delgado L, Roujeau JC, Le Cleach L, Fleming-Torrinha JA (2002) Soluble interleukin 2 receptor and interleukin 1alpha in toxic epidermal necrolysis: a comparative analysis of serum and blister fluid samples. Arch Dermatol 138(1):29–32 Nassif A, Bensussan A, Boumsell L, Deniaud A, Moslehi H, Wolkenstein P, Bagot M, Roujeau JC (2004) Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol 114(5):1209–1215. https://doi.org/10.1016/j.jaci.2004.07.047 Teraki Y, Kawabe M, Izaki S (2013) Possible role of TH17 cells in the pathogenesis of Stevens-Johnson syndrome and toxic epidermal necrolysis. J Allergy Clin Immunol 131(3):907–909. https://doi.org/10.1016/j.jaci.2012.08.042 Abe R, Shimizu T, Shibaki A, Nakamura H, Watanabe H, Shimizu H (2003) Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. Am J Pathol 162(5):1515–1520. https://doi.org/10.1016/s0002-9440(10)64284-8 Viard-Leveugle I, Gaide O, Jankovic D, Feldmeyer L, Kerl K, Pickard C, Roques S, Friedmann PS, Contassot E, French LE (2013) TNF-alpha and IFN-gamma are potential inducers of Fas-mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis. J Invest Dermatol 133(2):489–498. https://doi.org/10.1038/jid.2012.330 Nassif A, Moslehi H, Le Gouvello S, Bagot M, Lyonnet L, Michel L, Boumsell L, Bensussan A, Roujeau JC (2004) Evaluation of the potential role of cytokines in toxic epidermal necrolysis. J Invest Dermatol 123(5):850–855. https://doi.org/10.1111/j.0022-202X.2004.23439.x Posadas SJ, Padial A, Torres MJ, Mayorga C, Leyva L, Sanchez E, Alvarez J, Romano A, Juarez C, Blanca M (2002) Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity. J Allergy Clin Immunol 109(1):155–161 Inachi S, Mizutani H, Shimizu M (1997) Epidermal apoptotic cell death in erythema multiforme and Stevens-Johnson syndrome. Contribution of perforin-positive cell infiltration. Arch Dermatol 133(7):845–849 Nassif A, Bensussan A, Dorothee G, Mami-Chouaib F, Bachot N, Bagot M, Boumsell L, Roujeau JC (2002) Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J Invest Dermatol 118(4):728–733. https://doi.org/10.1046/j.1523-1747.2002.01622.x de Araujo E, Dessirier V, Lapree G, Valeyrie-Allanore L, Ortonne N, Stathopoulos EN, Bagot M, Bensussan A, Mockenhaupt M, Roujeau JC, Tsapis A (2011) Death ligand TRAIL, secreted by CD1a+ and CD14+ cells in blister fluids, is involved in killing keratinocytes in toxic epidermal necrolysis. Exp Dermatol 20(2):107–112. https://doi.org/10.1111/j.1600-0625.2010.01176.x Morel E, Escamochero S, Cabanas R, Diaz R, Fiandor A, Bellon T (2010) CD94/NKG2C is a killer effector molecule in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Allergy Clin Immunol 125(3):703–710, 710.e701-710.e708. https://doi.org/10.1016/j.jaci.2009.10.030 Schlapbach C, Zawodniak A, Irla N, Adam J, Hunger RE, Yerly D, Pichler WJ, Yawalkar N (2011) NKp46+ cells express granulysin in multiple cutaneous adverse drug reactions. Allergy 66(11):1469–1476. https://doi.org/10.1111/j.1398-9995.2011.02677.x Yang CW, Hung SI, Juo CG, Lin YP, Fang WH, Lu IH, Chen ST, Chen YT (2007) HLA-B*1502-bound peptides: implications for the pathogenesis of carbamazepine-induced Stevens-Johnson syndrome. J Allergy Clin Immunol 120(4):870–877. https://doi.org/10.1016/j.jaci.2007.06.017 Wei CY, Chung WH, Huang HW, Chen YT, Hung SI (2012) Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. J Allergy Clin Immunol 129(6):1562–1569.e1565. https://doi.org/10.1016/j.jaci.2011.12.990 Ko TM, Chung WH, Wei CY, Shih HY, Chen JK, Lin CH, Chen YT, Hung SI (2011) Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. J Allergy Clin Immunol 128(6):1266–1276.e1211. https://doi.org/10.1016/j.jaci.2011.08.013 Chung WH, Pan RY, Chu MT, Chin SW, Huang YL, Wang WC, Chang JY, Hung SI (2015) Oxypurinol-specific T cells possess preferential TCR clonotypes and express granulysin in allopurinol-induced severe cutaneous adverse reactions. J Invest Dermatol 135(9):2237–2248. https://doi.org/10.1038/jid.2015.165 Sekula P, Dunant A, Mockenhaupt M, Naldi L, Bouwes Bavinck JN, Halevy S, Kardaun S, Sidoroff A, Liss Y, Schumacher M, Roujeau JC (2013) Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol 133(5):1197–1204. https://doi.org/10.1038/jid.2012.510 Oplatek A, Brown K, Sen S, Halerz M, Supple K, Gamelli RL (2006) Long-term follow-up of patients treated for toxic epidermal necrolysis. J Burn Care Res 27(1):26–33. https://doi.org/10.1097/01.bcr.0000194268.01514.f8 Wang L, Mei XL (2017) Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 88 Chinese patients. Chin Med J 130(9):1062–1068. https://doi.org/10.4103/0366-6999.204929 Tocco-Tussardi I, Huss F, Presman B (2017) Microbiological findings and antibacterial therapy in Stevens-Johnson syndrome/toxic epidermal necrolysis patients from a Swedish Burn Center. J Cutan Pathol 44(5):420–432. https://doi.org/10.1111/cup.12894 McGee T, Munster A (1998) Toxic epidermal necrolysis syndrome: mortality rate reduced with early referral to regional burn center. Plast Reconstr Surg 102(4):1018–1022 Hermiz SJ, Diegidio P, Ortiz-Pujols S, Garimella R, Weber DJ, van Duin D, Hultman CS (2017) Life-threatening skin disorders treated in the Burn Center: impact of health care-associated infections on length of stay, survival, and hospital charges. Clin Plast Surg 44(3):597–602. https://doi.org/10.1016/j.cps.2017.02.006 Monteiro D, Egipto P, Barbosa J, Horta R, Amarante J, Silva P, Silva A (2017) Nine years of a single referral center management of Stevens-Johnson syndrome and toxic epidermal necrolysis (Lyell’s syndrome). Cutan Ocul Toxicol 36(2):163–168. https://doi.org/10.1080/15569527.2016.1218501 Weinand C, Xu W, Perbix W, Lefering R, Maegele M, Rathert M, Spilker G (2013) 27 years of a single burn centre experience with Stevens-Johnson syndrome and toxic epidermal necrolysis: analysis of mortality risk for causative agents. Burns 39(7):1449–1455. https://doi.org/10.1016/j.burns.2013.03.011 Pinheiro S, Carvalho R, Ramos S, Diogo C, Caetano M, Cabral L, Cruzeiro C (2013) Toxic epidermal necrolysis: the experience of Coimbra’s burn unit. Acta Medica Port 26(4):341–348 de Prost N, Mekontso-Dessap A, Valeyrie-Allanore L, Van Nhieu JT, Duong TA, Chosidow O, Wolkenstein P, Brun-Buisson C, Maitre B (2014) Acute respiratory failure in patients with toxic epidermal necrolysis: clinical features and factors associated with mechanical ventilation. Crit Care Med 42(1):118–128. https://doi.org/10.1097/CCM.0b013e31829eb94f Lebargy F, Wolkenstein P, Gisselbrecht M, Lange F, Fleury-Feith J, Delclaux C, Roupie E, Revuz J, Roujeau JC (1997) Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. Intensive Care Med 23(12):1237–1244 Duong TA, de Prost N, Ingen-Housz-Oro S, Carrie AS, Zerah F, Valeyrie-Allanore L, Bagot M, Chosidow O, Roujeau JC, Wolkenstein P, Maitre B (2015) Stevens-Johnson syndrome and toxic epidermal necrolysis: follow-up of pulmonary function after remission. Br J Dermatol 172(2):400–405. https://doi.org/10.1111/bjd.13505 Bequignon E, Duong TA, Sbidian E, Valeyrie-Allanore L, Ingen-Housz-Oro S, Chatelin V, Coste A, Wolkenstein P, Chosidow O, Papon JF (2015) Stevens-Johnson syndrome and toxic epidermal necrolysis: ear, nose, and throat description at acute stage and after remission. JAMA Dermatol 151(3):302–307. https://doi.org/10.1001/jamadermatol.2014.4844 Pannu BS, Egan AM, Iyer VN (2016) Phenytoin induced Steven-Johnson syndrome and bronchiolitis obliterans—case report and review of literature. Respir Med Case Rep 17:54–56. https://doi.org/10.1016/j.rmcr.2016.01.006 Lamireau T, Leaute-Labreze C, Le Bail B, Taieb A (2001) Esophageal involvement in Stevens-Johnson syndrome. Endoscopy 33(6):550–553. https://doi.org/10.1055/s-2001-15091 Belafsky PC, Postma GN, Koufman JA, Bach KK (2002) Stevens-Johnson syndrome with diffuse esophageal involvement. Ear Nose Throat J 81(4):220 Mahe A, Keita S, Blanc L, Bobin P (1993) Esophageal necrosis in the Stevens-Johnson syndrome. J Am Acad Dermatol 29(1):103–104 Njei B, Schoenfeld A, Vaziri H (2013) Esophageal stricture secondary to drug-induced toxic epidermal necrolysis presenting in an adult: an unusual complication of a rare disease. Conn Med 77(9):541–544 Misra SP, Dwivedi M, Misra V (2004) Esophageal stricture as a late sequel of Stevens-Johnson syndrome in adults: incidental detection because of foreign body impaction. Gastrointest Endosc 59(3):437–440 Carter FM, Mitchell CK (1993) Toxic epidermal necrolysis—an unusual cause of colonic perforation. Report of a case. Dis Colon Rectum 36(8):773–777 Heye P, Descloux A, Singer G, Rosenberg R, Kocher T (2014) Perforated sigmoid diverticulitis in the presence of toxic epidermal necrolysis. Case Rep Dermatol 6(1):49–53. https://doi.org/10.1159/000360129 Meneux E, Wolkenstein P, Haddad B, Roujeau JC, Revuz J, Paniel BJ (1998) Vulvovaginal involvement in toxic epidermal necrolysis: a retrospective study of 40 cases. Obstet Gynecol 91(2):283–287 Petukhova TA, Maverakis E, Ho B, Sharon VR (2016) Urogynecologic complications in Stevens-Johnson syndrome and toxic epidermal necrolysis: Presentation of a case and recommendations for management. JAAD Case Rep 2(3):202–205. https://doi.org/10.1016/j.jdcr.2016.03.006 Yamane Y, Matsukura S, Watanabe Y, Yamaguchi Y, Nakamura K, Kambara T, Ikezawa Z, Aihara M (2016) Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients—treatment and outcome. Allergol Int 65(1):74–81. https://doi.org/10.1016/j.alit.2015.09.001 Hung CC, Liu WC, Kuo MC, Lee CH, Hwang SJ, Chen HC (2009) Acute renal failure and its risk factors in Stevens-Johnson syndrome and toxic epidermal necrolysis. Am J Nephrol 29(6):633–638. https://doi.org/10.1159/000195632 Agrawal P, Peter JV, George R (2013) Dermatological manifestations and relationship to outcomes of patients admitted to a medical intensive care unit: a study from a tertiary care hospital in India. Postgrad Med J 89(1055):501–507. https://doi.org/10.1136/postgradmedj-2012-131610 Morelli MS, O'Brien FX (2001) Stevens-Johnson syndrome and cholestatic hepatitis. Dig Dis Sci 46(11):2385–2388 Devarbhavi H, Raj S, Aradya VH, Rangegowda VT, Veeranna GP, Singh R, Reddy V, Patil M (2016) Drug-induced liver injury associated with Stevens-Johnson syndrome/toxic epidermal necrolysis: patient characteristics, causes, and outcome in 36 cases. Hepatology 63(3):993–999. https://doi.org/10.1002/hep.28270 Basturk A, Artan R, Yilmaz A, Gelen MT, Duman O (2016) Acute vanishing bile duct syndrome after the use of ibuprofen. Arab J Gastroenterol 17(3):137–139. https://doi.org/10.1016/j.ajg.2016.08.006 Srivastava M, Perez-Atayde A, Jonas MM (1998) Drug-associated acute-onset vanishing bile duct and Stevens-Johnson syndromes in a child. Gastroenterology 115(3):743–746 Taghian M, Tran TA, Bresson-Hadni S, Menget A, Felix S, Jacquemin E (2004) Acute vanishing bile duct syndrome after ibuprofen therapy in a child. J Pediatr 145(2):273–276. https://doi.org/10.1016/j.jpeds.2004.05.027 Okan G, Yaylaci S, Peker O, Kaymakoglu S, Saruc M (2008) Vanishing bile duct and Stevens-Johnson syndrome associated with ciprofloxacin treated with tacrolimus. World J Gastroenterol 14(29):4697–4700 Harimoto N, Wang H, Ikegami T, Takeishi K, Itoh S, Yamashita YI, Yoshizumi T, Aishima S, Shirabe K, Oda Y, Maehara Y (2015) Education and Imaging. Hepatology: rare Stevens-Johnson syndrome and vanishing bile duct syndrome induced by acetaminophen, requiring liver transplantation. J Gastroenterol Hepatol 30(4):656. https://doi.org/10.1111/jgh.12849 Juricic D, Hrstic I, Radic D, Skegro M, Coric M, Vucelic B, Francetic I (2010) Vanishing bile duct syndrome associated with azithromycin in a 62-year-old man. Basic Clin Pharmacol Toxicol 106(1):62–65. https://doi.org/10.1111/j.1742-7843.2009.00474.x Garcia M, Mhanna MJ, Chung-Park MJ, Davis PH, Srivastava MD (2002) Efficacy of early immunosuppressive therapy in a child with carbamazepine-associated vanishing bile duct and Stevens-Johnson syndromes. Dig Dis Sci 47(1):177–182 White JC, Appleman S (2014) Infliximab/plasmapheresis in vanishing bile duct syndrome secondary to toxic epidermal necrolysis. Pediatrics 134(4):e1194–e1198. https://doi.org/10.1542/peds.2013-2239 Chow LLW, Shih KC, Chan JCY, Lai JSM, Ng ALK (2017) Comparison of the acute ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese eyes: a 15-year retrospective study. BMC Ophthalmol 17(1):65. https://doi.org/10.1186/s12886-017-0464-9 Gueudry J, Roujeau JC, Binaghi M, Soubrane G, Muraine M (2009) Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol 145(2):157–162. https://doi.org/10.1001/archdermatol.2009.540 Sotozono C, Ueta M, Nakatani E, Kitami A, Watanabe H, Sueki H, Iijima M, Aihara M, Ikezawa Z, Aihara Y, Kano Y, Shiohara T, Tohyama M, Shirakata Y, Kaneda H, Fukushima M, Kinoshita S, Hashimoto K (2015) Predictive factors associated with acute ocular involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis. Am J Ophthalmol 160(2):228–237.e222. https://doi.org/10.1016/j.ajo.2015.05.002 Di Pascuale MA, Espana EM, Liu DT, Kawakita T, Li W, Gao YY, Baradaran-Rafii A, Elizondo A, Raju VK, Tseng SC (2005) Correlation of corneal complications with eyelid cicatricial pathologies in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis syndrome. Ophthalmology 112(5):904–912. https://doi.org/10.1016/j.ophtha.2004.11.035 Ciralsky JB, Sippel KC, Gregory DG (2013) Current ophthalmologic treatment strategies for acute and chronic Stevens-Johnson syndrome and toxic epidermal necrolysis. Curr Opin Ophthalmol 24(4):321–328. https://doi.org/10.1097/ICU.0b013e3283622718 Tomlins PJ, Parulekar MV, Rauz S (2013) “Triple-TEN” in the treatment of acute ocular complications from toxic epidermal necrolysis. Cornea 32(3):365–369. https://doi.org/10.1097/ICO.0b013e318243fee3 Sotozono C, Ang LP, Koizumi N, Higashihara H, Ueta M, Inatomi T, Yokoi N, Kaido M, Dogru M, Shimazaki J, Tsubota K, Yamada M, Kinoshita S (2007) New grading system for the evaluation of chronic ocular manifestations in patients with Stevens-Johnson syndrome. Ophthalmology 114(7):1294–1302. https://doi.org/10.1016/j.ophtha.2006.10.029 Narang P, Mohamed A, Mittal V, Sangwan VS (2016) Cataract surgery in chronic Stevens-Johnson syndrome: aspects and outcomes. Br J Ophthalmol 100(11):1542–1546. https://doi.org/10.1136/bjophthalmol-2015-308041 Van Zyl L, Carrara H, Lecuona K (2014) Prevalence of chronic ocular complications in Stevens-Johnson syndrome and toxic epidermal necrolysis. Middle East Afr J Ophthalmol 21(4):332–335. https://doi.org/10.4103/0974-9233.142272 Kim DH, Yoon KC, Seo KY, Lee HS, Yoon SC, Sotozono C, Ueta M, Kim MK (2015) The role of systemic immunomodulatory treatment and prognostic factors on chronic ocular complications in Stevens-Johnson syndrome. Ophthalmology 122(2):254–264. https://doi.org/10.1016/j.ophtha.2014.08.013 Uy HS, Chan PS, Ang RE (2008) Topical bevacizumab and ocular surface neovascularization in patients with Stevens-Johnson syndrome. Cornea 27(1):70–73. https://doi.org/10.1097/ICO.0b013e318158f6ad Catt CJ, Hamilton GM, Fish J, Mireskandari K, Ali A (2016) Ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Am J Ophthalmol 166:68–75. https://doi.org/10.1016/j.ajo.2016.03.020 Yang CW, Cho YT, Chen KL, Chen YC, Song HL, Chu CY (2016) Long-term sequelae of Stevens-Johnson syndrome/toxic epidermal necrolysis. Acta Derm Venereol 96(4):525–529. https://doi.org/10.2340/00015555-2295 Kreft B, Lieser U, Haase R, Marsch WC, Wohlrab J (2014) Extensive hypertrophic scarring after toxic epidermal necrolysis in a child. Pediatr Dermatol 31(4):527–528. https://doi.org/10.1111/j.1525-1470.2012.01863.x Kavanagh GM, Page P, Hanna MM (1994) Silicone gel treatment of extensive hypertrophic scarring following toxic epidermal necrolysis. Br J Dermatol 130(4):540–541 Habre M, Ortonne N, Colin A, Meningaud JP, Chosidow O, Wolkenstein P, Valeyrie-Allanore L (2016) Facial scars following toxic epidermal necrolysis: role of adnexal involvement? Dermatology 232(2):220–223. https://doi.org/10.1159/000443164 Paquet P, Jacob E, Quatresooz P, Jacquemin D, Pierard GE (2007) Delayed reepithelialization and scarring deregulation following drug-induced toxic epidermal necrolysis. Burns 33(1):100–104. https://doi.org/10.1016/j.burns.2006.04.031 Lim VM, Do A, Berger TG, Nguyen AH, DeWeese J, Malone JD, Jordan K, Hom F, Tuffanelli L, Fillari P, Siu S, Grossman R (2016) A decade of burn unit experience with Stevens-Johnson syndrome/toxic epidermal necrolysis: clinical pathological diagnosis and risk factor awareness. Burns 42(4):836–843. https://doi.org/10.1016/j.burns.2016.01.014 McCullough M, Burg M, Lin E, Peng D, Garner W (2017) Steven Johnson Syndrome and Toxic Epidermal Necrolysis in a burn unit: A 15-year experience. Burns 43(1):200–205. https://doi.org/10.1016/j.burns.2016.07.026 Garcia-Doval I, LeCleach L, Bocquet H, Otero XL, Roujeau JC (2000) Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol 136(3):323–327 Xia W, Mao C, Luo X, Xu J, Chen X, Lin C (2016) A 13-year retrospective study evaluating the efficacy of using air-fluidised beds for toxic epidermal necrolysis patients. Australas J Dermatol 57(3):205–209. https://doi.org/10.1111/ajd.12318 Curtis JA, Christensen LC, Paine AR, Collins Brummer G, Summers EM, Cochran AL, Petersen MJ, Hull CM (2016) Stevens-Johnson syndrome and toxic epidermal necrolysis treatments: an Internet survey. J Am Acad Dermatol 74(2):379–380. https://doi.org/10.1016/j.jaad.2015.08.033 Seczynska B, Nowak I, Sega A, Kozka M, Wodkowski M, Krolikowski W, Szczeklik W (2013) Supportive therapy for a patient with toxic epidermal necrolysis undergoing plasmapheresis. Crit Care Nurse 33(4):26–38. https://doi.org/10.4037/ccn2013555 Dodiuk-Gad RP, Chung WH, Valeyrie-Allanore L, Shear NH (2015) Stevens-Johnson syndrome and toxic epidermal necrolysis: an update. Am J Clin Dermatol 16(6):475–493. https://doi.org/10.1007/s40257-015-0158-0 Dodiuk-Gad RP, Olteanu C, Feinstein A, Hashimoto R, Alhusayen R, Whyte-Croasdaile S, Finkelstein Y, Burnett M, Sade S, Cartotto R, Jeschke M, Shear NH (2016) Major psychological complications and decreased health-related quality of life among survivors of Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 175(2):422–424. https://doi.org/10.1111/bjd.14799 Butt TF, Cox AR, Lewis H, Ferner RE (2011) Patient experiences of serious adverse drug reactions and their attitudes to medicines: a qualitative study of survivors of Stevens-Johnson syndrome and toxic epidermal necrolysis in the UK. Drug Saf 34(4):319–328. https://doi.org/10.2165/11588460-000000000-00000 Kardaun SH, Jonkman MF (2007) Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis. Acta Derm Venereol 87(2):144–148. https://doi.org/10.2340/00015555-0214 Tripathi A, Ditto AM, Grammer LC, Greenberger PA, McGrath KG, Zeiss CR, Patterson R (2000) Corticosteroid therapy in an additional 13 cases of Stevens-Johnson syndrome: a total series of 67 cases. Allergy Asthma Proc 21(2):101–105 Lee HY, Dunant A, Sekula P, Mockenhaupt M, Wolkenstein P, Valeyrie-Allanore L, Naldi L, Halevy S, Roujeau JC (2012) The role of prior corticosteroid use on the clinical course of Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control analysis of patients selected from the multinational EuroSCAR and RegiSCAR studies. Br J Dermatol 167(3):555–562. https://doi.org/10.1111/j.1365-2133.2012.11074.x Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mockenhaupt M (2008) Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol 58(1):33–40. https://doi.org/10.1016/j.jaad.2007.08.039 Zimmermann S, Sekula P, Venhoff M, Motschall E, Knaus J, Schumacher M, Mockenhaupt M (2017) Systemic immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol 153(6):514–522. https://doi.org/10.1001/jamadermatol.2016.5668 Araki Y, Sotozono C, Inatomi T, Ueta M, Yokoi N, Ueda E, Kishimoto S, Kinoshita S (2009) Successful treatment of Stevens-Johnson syndrome with steroid pulse therapy at disease onset. Am J Ophthalmol 147(6):1004–1011, 1011.e1001. https://doi.org/10.1016/j.ajo.2008.12.040 Kim HI, Kim SW, Park GY, Kwon EG, Kim HH, Jeong JY, Chang HH, Lee JM, Kim NS (2012) Causes and treatment outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in 82 adult patients. Korean J Intern Med 27(2):203–210. https://doi.org/10.3904/kjim.2012.27.2.203 Das S, Roy AK, Biswas I (2013) A six-month prospective study to find out the treatment outcome, prognosis and offending drugs in toxic epidermal necrolysis from an urban institution in kolkata. Indian J Dermatol 58(3):191–193. https://doi.org/10.4103/0019-5154.110826 Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, Hunziker T, Saurat JH, Tschopp J, French LE (1998) Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282(5388):490–493 Prins C, Vittorio C, Padilla RS, Hunziker T, Itin P, Forster J, Brocker EB, Saurat JH, French LE (2003) Effect of high-dose intravenous immunoglobulin therapy in Stevens-Johnson syndrome: a retrospective, multicenter study. Dermatology 207(1):96–99 Prins C, Kerdel FA, Padilla RS, Hunziker T, Chimenti S, Viard I, Mauri DN, Flynn K, Trent J, Margolis DJ, Saurat JH, French LE (2003) Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 139(1):26–32 Trent JT, Kirsner RS, Romanelli P, Kerdel FA (2003) Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: the University of Miami experience. Arch Dermatol 139(1):39–43 Lee HY, Lim YL, Thirumoorthy T, Pang SM (2013) The role of intravenous immunoglobulin in toxic epidermal necrolysis: a retrospective analysis of 64 patients managed in a specialized centre. Br J Dermatol 169(6):1304–1309. https://doi.org/10.1111/bjd.12607 Huang YC, Chien YN, Chen YT, Li YC, Chen TJ (2016) Intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis. G Ital Dermatol Venereol 151(5):515–524 Jagadeesan S, Sobhanakumari K, Sadanandan SM, Ravindran S, Divakaran MV, Skaria L, Kurien G (2013) Low dose intravenous immunoglobulins and steroids in toxic epidermal necrolysis: a prospective comparative open-labelled study of 36 cases. Indian J Dermatol Venereol Leprol 79(4):506–511. https://doi.org/10.4103/0378-6323.113080 Aires DJ, Fraga G, Korentager R, Richie CP, Aggarwal S, Wick J, Liu DY (2013) Early treatment with nonsucrose intravenous immunoglobulin in a burn unit reduces toxic epidermal necrolysis mortality. J Drugs Dermatol 12(6):679–684 Arevalo JM, Lorente JA, Gonzalez-Herrada C, Jimenez-Reyes J (2000) Treatment of toxic epidermal necrolysis with cyclosporin A. J Trauma 48(3):473–478 Valeyrie-Allanore L, Wolkenstein P, Brochard L, Ortonne N, Maitre B, Revuz J, Bagot M, Roujeau JC (2010) Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 163(4):847–853. https://doi.org/10.1111/j.1365-2133.2010.09863.x Singh GK, Chatterjee M, Verma R (2013) Cyclosporine in Stevens Johnson syndrome and toxic epidermal necrolysis and retrospective comparison with systemic corticosteroid. Indian J Dermatol Venereol Leprol 79(5):686–692. https://doi.org/10.4103/0378-6323.116738 Mohanty S, Das A, Ghosh A, Sil A, Gharami RC, Bandyopadhyay D, Das NK (2017) Effectiveness, safety and tolerability of cyclosporine versus supportive treatment in Stevens-Johnson syndrome/toxic epidermal necrolysis: a record-based study. Indian J Dermatol Venereol Leprol 83(3):312–316. https://doi.org/10.4103/ijdvl.IJDVL_201_16 Lee HY, Fook-Chong S, Koh HY, Thirumoorthy T, Pang SM (2017) Cyclosporine treatment for Stevens-Johnson syndrome/toxic epidermal necrolysis: retrospective analysis of a cohort treated in a specialized referral center. J Am Acad Dermatol 76(1):106–113. https://doi.org/10.1016/j.jaad.2016.07.048 Kirchhof MG, Miliszewski MA, Sikora S, Papp A, Dutz JP (2014) Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine. J Am Acad Dermatol 71(5):941–947. https://doi.org/10.1016/j.jaad.2014.07.016 Gonzalez-Herrada C, Rodriguez-Martin S, Cachafeiro L, Lerma V, Gonzalez O, Lorente JA, Rodriguez-Miguel A, Gonzalez-Ramos J, Roustan G, Ramirez E, Bellon T, de Abajo FJ (2017) Ciclosporin use in epidermal necrolysis is associated with an important mortality reduction: evidence from three different approaches. J Invest Dermatol. https://doi.org/10.1016/j.jid.2017.05.022 Giudice G, Maggio G, Bufano L, Memeo G, Vestita M (2017) Management of toxic epidermal necrolysis with plasmapheresis and cyclosporine a: our 10 years’ experience. Plast Reconstr Surg Glob Open 5(2):e1221. https://doi.org/10.1097/gox.0000000000001221 Atanaskovic-Markovic M, Medjo B, Gavrovic-Jankulovic M, Cirkovic Velickovic T, Nikolic D, Nestorovic B (2013) Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Pediatr Allergy Immunol 24(7):645–649. https://doi.org/10.1111/pai.12121 Koh MJ, Tay YK (2009) An update on Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Curr Opin Pediatr 21(4):505–510. https://doi.org/10.1097/MOP.0b013e32832d1fef Koh MJ, Tay YK (2010) Stevens-Johnson syndrome and toxic epidermal necrolysis in Asian children. J Am Acad Dermatol 62(1):54–60. https://doi.org/10.1016/j.jaad.2009.06.085 St John J, Ratushny V, Liu KJ, Bach DQ, Badri O, Gracey LE, Ho AW, Raff AB, Sugai DY, Schalock P, Kroshinsky D (2017) Successful use of cyclosporin A for Stevens-Johnson syndrome and toxic epidermal necrolysis in three children. Pediatr Dermatol 34(5):540–546. https://doi.org/10.1111/pde.13236 Han F, Zhang J, Guo Q, Feng Y, Gao Y, Guo L, Hou Y, An J, Wang X, Yan B, Zheng Y, Song J, Li M, Wang G (2017) Successful treatment of toxic epidermal necrolysis using plasmapheresis: a prospective observational study. J Crit Care 42:65–68. https://doi.org/10.1016/j.jcrc.2017.07.002 Wolkenstein P, Latarjet J, Roujeau JC, Duguet C, Boudeau S, Vaillant L, Maignan M, Schuhmacher MH, Milpied B, Pilorget A, Bocquet H, Brun-Buisson C, Revuz J (1998) Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 352(9140):1586–1589. https://doi.org/10.1016/s0140-6736(98)02197-7 Paradisi A, Abeni D, Bergamo F, Ricci F, Didona D, Didona B (2014) Etanercept therapy for toxic epidermal necrolysis. J Am Acad Dermatol 71(2):278–283. https://doi.org/10.1016/j.jaad.2014.04.044 Chong I, Chao A (2017) Stevens-Johnson syndrome/toxic epidermal necrolysis and treatment with a biologic: a case report. Perm J 21. https://doi.org/10.7812/tpp/16-060 Didona D, Paolino G, Garcovich S, Caposiena Caro RD, Didona B (2016) Successful use of etanercept in a case of toxic epidermal necrolysis induced by rituximab. J Eur Acad Dermatol Venereol 30(10):e83–e84. https://doi.org/10.1111/jdv.13330 Hunger RE, Hunziker T, Buettiker U, Braathen LR, Yawalkar N (2005) Rapid resolution of toxic epidermal necrolysis with anti-TNF-alpha treatment. J Allergy Clin Immunol 116(4):923–924. https://doi.org/10.1016/j.jaci.2005.06.029 Fischer M, Fiedler E, Marsch WC, Wohlrab J (2002) Antitumour necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis. Br J Dermatol 146(4):707–709